Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
514.5 CHF | -0.35% |
|
-0.35% | +19.58% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 35.92 and 30.81 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.58% | 218B | - | ||
+9.90% | 189B | B- | ||
+26.47% | 151B | B- | ||
+31.87% | 113B | A- | ||
-0.15% | 64.02B | A- | ||
+12.89% | 52.6B | B+ | ||
+1.85% | 49.85B | B+ | ||
-6.07% | 37.89B | A | ||
-0.61% | 34.92B | - | ||
+22.06% | 31.1B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- TMO Stock
- TFS Stock
- Ratings Thermo Fisher Scientific